Analysis of the mechanism of action and clinical treatment principles of Lynparza

Olaparib (Olaparib) is an oral PARP (polyADPribose polymerase) inhibitor. It is mainly used to treat patients with breast, ovarian, prostate and pancreatic cancer who carry BRCA1/2 mutations. PARPenzyme plays a key role in the repair process of DNA single-strand breaks. Inhibiting PARP activity can block the DNA damage repair pathway, making cancer cells unable to effectively repair gene damage, thereby inducing cell death.

Olaparib's treatment principle is based on the "synthetic lethality" mechanism. In normal cells, even if PARP is inhibited, cells can still repair DNA damage through homologous recombination repair (HRR) pathway. However, in BRCA1/2 mutated tumor cells, the homologous recombination repair function is impaired. When PARP activity is inhibited, DNA damage cannot be repaired, eventually leading to tumor cell death, while having a relatively small impact on normal cells, enabling precise targeted therapy.

Clinical studies have shown that olaparib can significantly prolong progression-free survival (PFS) and improve the overall response rate (ORR) of some patients in advanced BRCA mutation-related tumors. The drug can be used as maintenance treatment to delay disease recurrence, or as first-line or second-line treatment for recurrent tumors. It is especially suitable for patients who have poor tolerance to chemotherapy or who have failed multiple chemotherapy treatments.

In practical applications, oral administration of olaparib is convenient, but patient tolerance and adverse reactions still need to be paid attention to. Common side effects include anemia, thrombocytopenia, gastrointestinal discomfort, and fatigue. Doctors usually adjust the dose based on the patient's blood picture and liver and kidney function, and combine it with chemotherapy or other targeted drugs for comprehensive treatment to achieve safe and precise tumor management.

Reference link:https://www.drugs.com